跳至主要内容
临床试验/NCT02500498
NCT02500498已完成不适用

Safety Profile of Nulojix in Home Infusion Settings

Bristol-Myers Squibb0 个研究点目标入组 37 人开始时间: 2014年10月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
37
主要终点
Proportion of infusion related serious adverse events in adult kidney-only transplant recipients who are treated with belatacept in home infusion settings

研究概览

简要总结

The study is a retrospective cohort study that utilizes medical records from the BiologicTx. Data accrual starts upon initial home infusion nurse visit until the most recent home infusion nurse visit. Infusion related adverse events are quantified as number of patients with adverse event over the total number of patients and number of event over total number of home infusion visits.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All adult kidney-only transplant recipients currently receiving NULOJIX in BiologicTx home infusion service settings

排除标准

  • 未提供

结局指标

主要结局

Proportion of infusion related serious adverse events in adult kidney-only transplant recipients who are treated with belatacept in home infusion settings

时间窗: 24 hours after the date of a home infusion visit

次要结局

未报告次要终点

研究者

发起方
Bristol-Myers Squibb
申办方类型
Industry
责任方
Sponsor

相似试验